Finding new drug targets for the treatment of migraine attacks

Cephalalgia

Volumn 29, Issue 9, 2009, Pages 909-920

  Olesen, J ^a   Tfelt Hansen, P ^a   Ashina, M ^a  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

Animal models of migraine; Drug targets; Human models of migraine; Migraine

Indexed keywords

4 (2 METHOXYPHENYL) 2 [2 (2 METHOXYPHENYL)PROPIONYL] 7,7 DIPHENYLPERHYDROISOINDOL 4 OL; 5 METHYLAMINOSULFONYLMETHYL 3 (1 METHYL 2 PYRROLIDINYLMETHYL) 1H INDOLE; ACETYLSALICYLIC ACID; APREPITANT; BOSENTAN; CALCITONIN GENE RELATED PEPTIDE RECEPTOR; CALCITONIN GENE RELATED PEPTIDE RECEPTOR ANTAGONIST; DIHYDROERGOTAMINE; ELETRIPTAN; ERGOTAMINE; LANEPITANT; MEPYRAMINE; MK 0974; N(G) METHYLARGININE; NARATRIPTAN; NITRIC OXIDE SYNTHASE; NITRIC OXIDE SYNTHASE INHIBITOR; NONSTEROID ANTIINFLAMMATORY AGENT; OLCEGEPANT; S [2 (1 IMINOETHYLAMINO)ETHYL]HOMOCYSTEINE; SUMATRIPTAN; UNCLASSIFIED DRUG; VOFOPITANT; ZOLMITRIPTAN;

CLINICAL TRIAL; DRUG MECHANISM; DRUG RESEARCH; DRUG TARGETING; ENZYME INHIBITION; HEADACHE; HUMAN; MIGRAINE; REVIEW;

ANALGESICS, NON-NARCOTIC; ANIMALS; CALCITONIN GENE-RELATED PEPTIDE; DISEASE MODELS, ANIMAL; DRUG DISCOVERY; HUMANS; MIGRAINE DISORDERS; NITRIC OXIDE SYNTHASE;

EID: 68249102634     PISSN: 03331024     EISSN: 14682982     Source Type: Journal    
DOI: 10.1111/j.1468-2982.2008.01837.x     Document Type: Review

References (116)

1. Andlin-Sobocki P, Jonsson B, Wittchen HU, Olesen J. Cost of disorders of the brain in Europe. Eur J Neurol 2005 12 (Suppl. 1 1 27.
2. Lipton RB, Bigal ME, Diamond M, Freitag F, Reed ML, Stewart WF. Migraine prevalence, disease burden, and the need for preventive therapy. Neurology 2007 68 : 343 9.
3. Migraine mechanisms. In : Olesen J, Goadsby P, Ramadan N, Tfelt-Hansen P, Welch KM, eds. The headches. Philadelphia, PA : Lippincott Williams & Wilkins 2006 : 251 398.
4. Humphrey PP, Feniuk W, Perren MJ, Connor HE, Oxford AW. The pharmacology of the novel 5-HT1-like receptor agonist, GR43175. Cephalalgia 1989 9 (Suppl. 9 23 33.
5. Humphrey PP. The discovery of a new drug class for the acute treatment of migraine. Headache 2007 47 (Suppl. 1 S10 19.
6. Patten JP. Clinical experience with oral sumatriptan: a placebo-controlled, dose-ranging study. Oral Sumatriptan Dose-Defining Study Group. J Neurol 1991 238 (Suppl. 1 S62 5.
7. Ferrari MD, Roon KI, Lipton RB, Goadsby PJ. Oral triptans (serotonin 5-HT(1B\1D) agonists) in acute migraine treatment: a meta-analysis of 53 trials. Lancet 2001 358 : 1668 75.
8. Tfelt-Hansen P, De Vries P, Saxena PR. Triptans in migraine: a comparative review of pharmacology, pharmacokinetics and efficacy. Drugs 2000 60 : 1259 87.
9. Tfelt-Hansen P, Rolan P. Beta-andrenoreceptor blocking drugs in migraine prophylaxis. In : Olesen J, Goadsby P, Ramadan N, Tfelt-Hansen P, Welch KM, eds. The headaches. Philadelphia, PA : Lippincott Williams & Wilkins 2006 : 519 28.
10. Andersson KE, Vinge E. Beta-adrenoceptor blockers and calcium antagonists in the prophylaxis and treatment of migraine. Drugs 1990 39 : 355 73.
11. Tfelt-Hansen P, Steiner TJ. Over-the-counter triptans for migraine: what are the implications? CNS Drugs 2007 21 : 877 83.
12. Diener HC, Lampl C, Reimnitz P, Voelker M. Aspirin in the treatment of acute migraine attacks. Expert Rev Neurother 2006 6 : 563 73.
13. Stoll A. Zur Kenntnis der Mutterkornalkaloide. Verh Schweiz Naturf Ges 1918 101 : 190 1.
14. Maier HW. L'ergotamine inhibitteur du sympathique etudie en clinique, comme moyen d'exploration et comme agent therapeutique. Rev Neurol (Paris) 1926 33 : 1104 8.
15. Graham JR, Wolff HG. Mechanism of migraine headache and action of ergotamine tartrate. Arch Neurol Psychiat 1938 39 : 737.
16. Tfelt-Hansen P. The effect of ergotamine on the arterial system in man. Acta Pharmacol Toxicol (Copenh) 1986 59 (Suppl. 3 1 30.
17. Tfelt-Hansen P, Saxena PR. Ergot alkaloids in the acute treatment of migraine. In : Olesen J, Goadsby P, Ramadan N, Tfelt-Hansen P, Welch KM, eds. The headaches. Philadelphia, PA : Lippincott Williams & Wilkins 2006 : 459 67.
18. Fanchamps A, Doepfner W, Weidmann H, Cerletti A Pharmacological characterization of deseril, a serotonin antagonist Schweiz Med Wochenschr 1960 90 : 1040 6.
19. Sicuteri F. Prophylactic and therapeutic properties of 1-methyl-lysergic acid butanolamide in migraine. Int Arch Allergy Appl Immunol 1959 15 : 300 7.
20. Sicuteri F, Testi A, Anselmi B. Biochemical investigations in headache: increase in hydroxyindolacetic acid excretion during migraine attacks. Int Arch Allergy 1961 19 : 55 8.
21. Curran DA, Hinterberger H, Lance JW. Total plasma serotonin, 5-hydroxyindoleacetic acid and p-hydroxy-m-methoxymandelic acid excretion in normal and migrainous subjects. Brain 1965 88 : 997 1010.
22. Anthony M, Hinterberger H, Lance JW. Studies of serotonin metabolism in migraine. Proc Aust Assoc Neurol 1968 5 : 109 12.
23. Lance JW, Anthony M, Hinterberger H. Serotonin and migraine. Trans Am Neurol Assoc 1967 92 : 128 31.
24. Anthony M, Hinterberger H, Lance JW. Plasma serotonin in migraine and stress. Arch Neurol 1967 16 : 544 52.
25. Lance JW, Anthony M. The effect of serotonin on cranial vessels and its significance in migraine. Proc Aust Assoc Neurol 1968 5 : 639 42.
26. Anthony M, Hinterberger H, Lance JW. Plasma serotonin in migraine and stress. Arch Neurol 1967 16 : 544 52.
27. Kimball RW, Friedman AP, Vallejo E. Effect of serotonin in migraine patients. Neurology 1960 10 : 107 11.
28. Doenicke A, Brand J, Perrin VL. Possible benefit of GR43175, a novel 5-HT1-like receptor agonist, for the acute treatment of severe migraine. Lancet 1988 1 : 1309 11.
29. Humphrey PP. The discovery of a new drug class for the acute treatment of migraine. Headache 2007 47 (Suppl. 1 S10 19.
30. Saxena PR, Verdouw PD. Effects of methysergide and 5-hydroxytryptamine on carotid blood flow distribution in pigs: further evidence for the presence of atypical 5-HT receptors. Br J Pharmacol 1984 82 : 817 26.
31. Forsyth RP, Saxena PR. The influence of methysergide on 5-hydroxytryptamine-induced changes in regional distribution of blood flow. J Pharm Pharmacol 1978 30 : 503 7.
32. Saito K, Markowitz S, Moskowitz MA. Ergot alkaloids block neurogenic extravasation in dura mater: proposed action in vascular headaches. Ann Neurol 1988 24 : 732 7.
33. Markowitz S, Saito K, Moskowitz MA. Neurogenically mediated plasma extravasation in dura mater: effect of ergot alkaloids. A possible mechanism of action in vascular headache. Cephalalgia 1988 8 : 83 91.
34. Moskowitz MA. The neurobiology of vascular head pain. Ann Neurol 1984 16 : 157 68.
35. Moskowitz MA. Neurogenic inflammation in the pathophysiology and treatment of migraine. Neurology 1993 43 (6 Suppl. 3 S16 20.
36. Buzzi MG, Moskowitz MA. Evidence for 5-HT1B\1D receptors mediating the antimigraine effect of sumatriptan and dihydroergotamine. Cephalalgia 1991 11 : 165 8.
37. Buzzi MG, Sakas DE, Moskowitz MA. Indomethacin and acetylsalicylic acid block neurogenic plasma protein extravasation in rat dura mater. Eur J Pharmacol 1989 165 : 251 8.
38. Goldstein DJ, Offen WW, Klein EG, Phebus LA, Hipskind P, Johnson KW et al. Lanepitant, an NK-1 antagonist, in migraine prevention. Cephalalgia 2001 21 : 102 6.
39. Goldstein DJ, Wang O, Saper JR, Stoltz R, Silberstein SD, Mathew NT. Ineffectiveness of neurokinin-1 antagonist in acute migraine: a crossover study. Cephalalgia 1997 17 : 785 90.
40. Gomez-Mancilla B, Cutler NR, Leibowitz MT, Spierings EL, Klapper JA, Diamond S et al. Safety and efficacy of PNU-142633, a selective 5-HT1D agonist, in patients with acute migraine. Cephalalgia 2001 21 : 727 32.
41. Roon KI, Olesen J, Diener HC, Ellis P, Hettiarachchi J, Poole PH et al. No acute antimigraine efficacy of CP-122,288, a highly potent inhibitor of neurogenic inflammation: results of two randomized, double-blind, placebo-controlled clinical trials. Ann Neurol 2000 47 : 238 41.
42. May A, Gijsman HJ, Wallnofer A, Jones R, Diener HC, Ferrari MD. Endothelin antagonist bosentan blocks neurogenic inflammation, but is not effective in aborting migraine attacks. Pain 1996 67 : 375 8.
43. Williamson DJ, Hargreaves RJ. Neurogenic inflammation in the context of migraine. Microsc Res Tech 2001 53 : 167 78.
44. Goadsby PJ, Hoskin KL, Knight YE. Substance P blockade with the potent and centrally acting antagonist GR205171 does not effect central trigeminal activity with superior sagittal sinus stimulation. Neuroscience 1998 86 : 337 43.
45. Goadsby PJ, Knight Y. Inhibition of trigeminal neurones after intravenous administration of naratriptan through an action at 5-hydroxy-tryptamine (5-HT(1B\1D)) receptors. Br J Pharmacol 1997 122 : 918 22.
46. Goadsby PJ, Hoskin KL. Inhibition of trigeminal neurons by intravenous administration of the serotonin (5HT)1B\D receptor agonist zolmitriptan (311C90): are brain stem sites therapeutic target in migraine? Pain 1996 67 : 355 9.
47. Hoskin KL, Goadsby PJ. Comparison of more and less lipophilic serotonin (5HT1B\1D) agonists in a model of trigeminovascular nociception in cat. Exp Neurol 1998 150 : 45 51.
48. Kaube H, Hoskin KL, Goadsby PJ. Inhibition by sumatriptan of central trigeminal neurones only after blood-brain barrier disruption. Br J Pharmacol 1993 109 : 788 92.
49. Storer RJ, Akerman S, Goadsby PJ. Calcitonin gene-related peptide (CGRP) modulates nociceptive trigeminovascular transmission in the cat. Br J Pharmacol 2004 142 : 1171 81.
50. Lambert GA, Lowy AJ, Boers PM, Angus-Leppan H, Zagami AS. The spinal cord processing of input from the superior sagittal sinus: pathway and modulation by ergot alkaloids. Brain Res 1992 597 : 321 30.
51. Strassman AM, Raymond SA, Burstein R. Sensitization of meningeal sensory neurons and the origin of headaches. Nature [0028-0836 1996 12 : 560 4.
52. Burstein R. Deconstructing migraine headache into peripheral and central sensitization. Pain 2001 89 : 107 10.
53. Levy D, Jakubowski M, Burstein R. Disruption of communication between peripheral and central trigeminovascular neurons mediates the antimigraine action of 5HT 1B\1D receptor agonists. Proc Natl Acad Sci USA 2004 101 : 4274 9.
54. Burstein R, Collins B, Jakubowski M. Defeating migraine pain with triptans: a race against the development of cutaneous allodynia. Ann Neurol 2004 55 : 19 26.
55. Shepherd SL, Williamson DJ, Beer MS, Hill RG, Hargreaves RJ. Differential effects of 5-HT1B\1D receptor agonists on neurogenic dural plasma extravasation and vasodilation in anaesthetized rats. Neuropharmacology 1997 36 : 525 33.
56. Akerman S, Williamson DJ, Hill RG, Goadsby PJ. The effect of adrenergic compounds on neurogenic dural vasodilatation. Eur J Pharmacol 2001 424 : 53 8.
57. Petersen KA, Birk S, Doods H, Edvinsson L, Olesen J. Inhibitory effect of BIBN4096BS on cephalic vasodilatation induced by CGRP or transcranial electrical stimulation in the rat. Br J Pharmacol 2004 143 : 697 704.
58. Akerman S, Williamson DJ, Kaube H, Goadsby PJ. The role of histamine in dural vessel dilation. Brain Res 2002 956 : 96 102.
59. Akerman S, Williamson DJ, Kaube H, Goadsby PJ. The effect of anti-migraine compounds on nitric oxide-induced dilation of dural meningeal vessels. Eur J Pharmacol 2002 452 : 223 8.
60. Holland PR, Akerman S, Goadsby PJ. Orexin 1 receptor activation attenuates neurogenic dural vasodilation in an animal model of trigeminovascular nociception. J Pharmacol Exp Ther 2005 315 : 1380 5.
61. Kowacs F, Williamson DJ, Goadsby PJ. Neurogenic vasodilation of dural blood vessels is not mediated by cholinergic transmission in the anaesthetised rat. Eur J Pharmacol 2004 493 : 133 7.
62. Petersen KA, Birk S, Doods H, Edvinsson L, Olesen J. Inhibitory effect of BIBN4096BS on cephalic vasodilatation induced by CGRP or transcranial electrical stimulation in the rat. Br J Pharmacol 2004 143 : 697 704.
63. Leão AAP. Spreading depression of activity in the cerebral cortex. J Neurophysiol 1944 359 90.
64. Lauritzen M, Skyhoj OT, Lassen NA, Paulson OB. Changes in regional cerebral blood flow during the course of classic migraine attacks. Ann Neurol 1983 13 : 633 41.
65. Olesen J, Vorstrup S, Lauritzen M. rCBF after TIA and during migraine attacks. Cephalalgia 1985 5 (Suppl. 2 43 6.
66. Lauritzen M. Cerebral blood flow in migraine and cortical spreading depression. Acta Neurol Scand Suppl 1987 113 : 1 40.
67. Olesen J, Larsen B, Lauritzen M. Focal hyperemia followed by spreading oligemia and impaired activation of rCBF in classic migraine. Ann Neurol 1981 9 : 344 52.
68. Hadjikhani N, Sanchez dR, Wu O, Schwartz D, Bakker D, Fischl B et al. Mechanisms of migraine aura revealed by functional MRI in human visual cortex. Proc Natl Acad Sci USA 2001 98 : 4687 92.
69. Cutrer FM, Sorensen AG, Weisskoff RM, Ostergaard L, Sanchez dR, Lee EJ et al. Perfusion-weighted imaging defects during spontaneous migrainous aura. Ann Neurol 1998 43 : 25 31.
70. Chan WN, Evans JM, Hadley MS, Herdon HJ, Jerman JC, Parsons AA et al. Identification of (-)-cis-6-acetyl-4S-(3-chloro-4-fluoro-benzoylamino)- 3,4-dihydro-2,2-dimethyl-2H-benzo[b]pyran-3S-ol as a potential antimigraine agent. Bioorg Med Chem Lett 1999 9 : 285 90.
71. Read SJ, Smith MI, Hunter AJ, Upton N, Parsons AA. SB-220453, a potential novel antimigraine agent, inhibits nitric oxide release following induction of cortical spreading depression in the anaesthetized cat. Cephalalgia 2000 20 : 92 9.
72. Goadsby PJ, Ferrari M, Olesen J, Mills JG on behalf of the Tonabersat TON-01-05 Study Group. Double-blind placebo-controlled trial of tonerbasat in the preventive management of migraine. Cephalalgia 2007 27 : 1195 6 Abstract SK, Kaube H, Goadsby PJ. Glyceryl trinitrate triggers premonitory symptoms in migraineurs. Pain 2004 110 : 675 80.
73. Olesen J, Iversen HK, Thomsen LL. Nitric oxide supersensitivity: a possible molecular mechanism of migraine pain. Neuroreport 1993 4 : 1027 30.
74. Thomsen LL, Iversen HK, Brinck TA, Olesen J. Arterial supersensitivity to nitric oxide (nitroglycerin) in migraine sufferers. Cephalalgia 1993 13 : 395 9.
75. Iversen HK, Olesen J, Tfelt-Hansen P. Intravenous nitroglycerin as an experimental model of vascular headache. Basic characteristics. Pain 1989 38 : 17 24.
76. Iversen HK, Holm S, Friberg L. Intracranial hemodynamics during intravenous nitroglycerin infusion. Cephalalgia 1989 9 (Suppl. 10 84 5.
77. Iversen HK, Nielsen TH, Garre K, Tfelt-Hansen P, Olesen J. Dose-dependent headache response and dilatation of limb and extracranial arteries after three doses of 5-isosorbide-mononitrate. Eur J Clin Pharmacol 1992 42 : 31 5.
78. Iversen HK, Nielsen TH, Tfelt-Hansen P, Olesen J. Lack of tolerance of headache and radial artery diameter during a 7 hour intravenous infusion of nitroglycerin. Eur J Clin Pharmacol 1993 44 : 47 50.
79. Lassen LH, Ashina M, Christiansen I, Ulrich V, Olesen J. Nitric oxide synthase inhibition in migraine [letter Lancet [0140-6736 1997 8 : 401 2.
80. de Hoon JN, Depre1 M, Guillard F, Laurijssens B, Lunnon MW, Palmer J et al. iNOS inhibition in acute migraine: pharmacokinetic characteristics, safety and tolerability of GW273629. Cephalalgia 2007 27 : 721 2.
81. Lassen LH, Thomsen LL, Olesen J. Histamine induces migraine via the H1-receptor. Support for the NO hypothesis of migraine. Neuroreport 1995 31 : 1475 9.
82. Lassen LH, Thomsen LL, Kruuse C, Iversen HK, Olesen J. Histamine-1 receptor blockade does not prevent nitroglycerin induced migraine. Support for the NO-hypothesis of migraine. Eur J Clin Pharmacol 1996 49 : 335 9.
83. Edvinsson L, Fredholm BB, Hamel E, Jansen I, Verrecchia C. Perivascular peptides relax cerebral arteries concomitant with stimulation of cyclic adenosine monophosphate accumulation or release of an endothelium-derived relaxing factor in the cat. Neurosci Lett 1985 58 : 213 17.
84. Uddman R, Edvinsson L, Ekman R, Kingman T, McCulloch J. Innervation of the feline cerebral vasculature by nerve fibers containing calcitonin gene-related peptide: trigeminal origin and co-existence with substance P. Neurosci Lett 1985 62 : 131 6.
85. Uddman R, Edvinsson L, Ekblad E, Hakanson R, Sundler F. Calcitonin gene-related peptide (CGRP): perivascular distribution and vasodilatory effects. Regul Pept 1986 15 : 1 23.
86. Edvinsson L, Alm R, Shaw D, Rutledge RZ, Koblan KS, Longmore J et al. Effect of the CGRP receptor antagonist BIBN4096BS in human cerebral, coronary and omental arteries and in SK-N-MC cells. Eur J Pharmacol 2002 434 : 49 53.
87. Goadsby PJ, Edvinsson L, Ekman R. Vasoactive peptide release in the extracerebral circulation of humans during migraine headache. Ann Neurol [0364-5134 1990 28 : 183 7.
88. Tvedskov JF, Lipka K, Ashina M, Iversen HK, Schifter S, Olesen J. No increase of calcitonin gene-related peptide in jugular blood during migraine. Ann Neurol 2005 58 : 561 8.
89. Lassen LH, Haderslev PA, Jacobsen VB, Iversen HK, Sperling B, Olesen J. CGRP may play a causative role in migraine. Cephalalgia 2002 22 : 54 61.
90. Doods H, Hallermayer G, Wu D, Entzeroth M, Rudolf K, Engel W et al. Pharmacological profile of BIBN4096BS, the first selective small molecule CGRP antagonist. Br J Pharmacol 2000 129 : 420 3.
91. Olesen J, Diener HC, Husstedt IW, Goadsby PJ, Hall D, Meier U et al. Calcitonin gene-related peptide receptor antagonist BIBN 4096 BS for the acute treatment of migraine. N Engl J Med 2004 350 : 1104 10.
92. Ho TW, Mannix LK, Fan X, Assaid C, Furtek C, Jones CJ et al. Randomized controlled trial of an oral CGRP antagonist, MK-0974, in acute treatment of migraine. Neurology 2008 70 : 1304 12.
93. Iversen HK, Olesen J, Tfelt-Hansen P. Intravenous nitroglycerin as an experimental model of vascular headache. Basic characteristics. Pain 1989 38 : 17 24.
94. Hansen JM, Sitarz J, Birk S, Rahmann AM, Oturai PS, Fahrenkrug J et al. Vasoactive intestinal polypeptide evokes only a minimal headache in healthy volunteers. Cephalalgia 2006 26 : 992 1003.
95. Thomsen LL, Kruuse C, Iversen HK, Olesen J. A nitric oxide donor (nitroglycerin) triggers genuine migraine attacks. Eur Neurol 1994 1 : 73 80.
96. Rahmann AM, Wienecke T, Hansen JM, Fabricius M, Olesen J, Ashina M. Vasoactive intestinal peptide causes marked cephalic vasodilatation but does not induce migraine. Cephalalgia 2008 28 : 226 36.
97. Birk S, Kruuse C, Petersen KA, Jonassen O, Tfelt-Hansen P, Olesen J. The phosphodiesterase 3 inhibitor cilostazol dilates large cerebral arteries in humans without affecting regional cerebral blood flow. J Cereb Blood Flow Metab 2004 24 : 1352 8.
98. Birk S, Petersen KA, Kruuse C, Guieu R, Jonassen O, Eisert W et al. The effect of circulating adenosine on cerebral haemodynamics and headache generation in healthy subjects. Cephalalgia 2005 25 : 369 77.
99. Petersen KA, Birk S, Lassen LH, Kruuse C, Jonassen O, Lesko L et al. The CGRP-antagonist, BIBN4096BS does not affect cerebral or systemic haemodynamics in healthy volunteers. Cephalalgia 2005 25 : 139 47.
100. Birk S, Kruuse C, Petersen KA, Tfelt-Hansen P, Olesen J. The headache-inducing effect of cilostazol in human volunteers. Cephalalgia 2006 26 : 1304 9.
101. Kruuse C, Frandsen E, Schifter S, Thomsen LL, Birk S, Olesen J. Plasma levels of cAMP, cGMP and CGRP in sildenafil-induced headache. Cephalalgia 2004 24 : 547 53.
102. Birk S, Petersen KA, Kruuse C, Guieu R, Jonassen O, Eisert W et al. The effect of circulating adenosine on cerebral haemodynamics and headache generation in healthy subjects. Cephalalgia 2005 25 : 369 77.
103. Reuter U, Bolay H, Jansen-Olesen I, Chiarugi A, Sanchez dR, Letourneau R et al. Delayed inflammation in rat meninges: implications for migraine pathophysiology. Brain 2001 124 : 2490 502.
104. Gursoy-Ozdemir Y, Qiu J, Matsuoka N, Bolay H, Bermpohl D, Jin H et al. Cortical spreading depression activates and upregulates MMP-9. J Clin Invest 2004 113 : 1447 55.
105. Amara SG, Jonas V, Rosenfeld MG, Ong ES, Evans RM. Alternative RNA processing in calcitonin gene expression generates mRNAs encoding different polypeptide products. Nature 1982 298 : 240 4.
106. Brain SD, Cambridge H. Calcitonin gene-related peptide: vasoactive effects and potential therapeutic role. Gen Pharmacol 1996 27 : 607 11.
107. Sexton PM. Central nervous system binding sites for calcitonin and calcitonin gene-related peptide. Mol Neurobiol 1991 5 : 251 73.
108. Rosenfeld MG, Mermod JJ, Amara SG, Swanson LW, Sawchenko PE, Rivier J et al. Production of a novel neuropeptide encoded by the calcitonin gene via tissue-specific RNA processing. Nature 1983 304 : 129 35.
109. Mason RT, Peterfreund RA, Sawchenko PE, Corrigan AZ, Rivier JE, Vale WW. Release of the predicted calcitonin gene-related peptide from cultured rat trigeminal ganglion cells. Nature 1984 308 : 653 5.
110. McCulloch J, Uddman R, Kingman TA, Edvinsson L. Calcitonin gene-related peptide: functional role in cerebrovascular regulation. Proc Natl Acad Sci USA 1986 83 : 5731 5.
111. Edvinsson L, Ekman R, Jansen I, Ottosson A, Uddman R. Peptide-containing nerve fibers in human cerebral arteries: immunocytochemistry, radioimmunoassay, and in vitro pharmacology. Ann Neurol 1987 21 : 431 7.
112. Jansen-Olesen I, Jorgensen L, Engel U, Edvinsson L. In-depth characterization of CGRP receptors in human intracranial arteries. Eur J Pharmacol 2003 481 : 207 16.
113. Goadsby PJ, Edvinsson L, Ekman R. Release of vasoactive peptides in the extracerebral circulation of humans and the cat during activation of the trigeminovascular system. Ann Neurol [0364-5134 1988 23 : 193 6.
114. Ashina M, Bendtsen L, Jensen R, Schifter S, Olesen J. Evidence for increased plasma levels of calcitonin gene-related peptide in migraine outside of attacks [in process citation Pain 2000 86 : 133 8.
115. Iversen HK, Nielsen TH, Olesen J, Tfelt-Hansen P. Arterial responses during migraine headache. Lancet 1990 336 : 837 9.
116. Headache Classification Subcommittee of the International Headache Society. The International Classification of Headache Disorders, 2nd edition. Cephalalgia 2004 24 (Suppl. 1 9 160.